A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19

drug protocol number

RC20/174/R

drug sponsor

KAIMRC

drug study

Favipiravir

drug trial site

NGHA-R

drug status

Terminated

drug phase